MARKET

CNAT

CNAT

Conatus Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.3722
+0.0032
+0.87%
Closed 16:00 12/09 EST
OPEN
0.3700
PREV CLOSE
0.3690
HIGH
0.3770
LOW
0.3600
VOLUME
406.36K
TURNOVER
--
52 WEEK HIGH
3.080
52 WEEK LOW
0.2500
MARKET CAP
12.35M
P/E (TTM)
-0.9630
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CNAT and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

CNAT News

  • Intercept (ICPT) Gains 7.5% YTD on Progress in NASH Space
  • Zacks.12/02 14:04
  • NASH Scorecard Year to Date: The Winners and the Losers
  • Zacks.11/29 13:41
  • UPDATE 1-CymaBay Therapeutics scraps liver disease studies; shares plunge
  • Reuters.11/25 14:14
  • Conatus Pharmaceuticals Appoints Kathy Scott as Independent Board Member
  • GlobeNewswire.11/18 21:05

More

Industry

Biotechnology & Medical Research
+0.53%
Pharmaceuticals & Medical Research
+0.23%

Hot Stocks

Name
Price
%Change

About CNAT

Conatus Pharmaceuticals Inc. is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease. Emricasan has the potential to interrupt the progression of liver disease and provide treatment options in multiple areas of liver disease. Emricasan is designed to slow or halt the progression of chronic liver disease caused by fibrosis and cirrhosis. Emricasan works by inhibiting caspases, which are a family of related enzymes that plays as modulators of critical cellular functions, including functions that result in apoptosis and inflammation.
More

Webull offers Conatus Pharmaceuticals Inc (CNAT) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.